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Abstract
Somatostatin receptor-targeting endoradiotherapy offers potential for treating metastatic 
pheochromocytomas and paragangliomas, an approach likely to benefit from combination 
radiosensitization therapy. To provide reliable preclinical in vivo models of metastatic 
disease, this study characterized the metastatic spread of luciferase-expressing mouse 
pheochromocytoma (MPC) cells in mouse strains with different immunologic conditions. 
Bioluminescence imaging showed that, in contrast to subcutaneous non-metastatic 
engraftment of luciferase-expressing MPC cells in NMRI-nude mice, intravenous cell injection 
provided only suboptimal metastatic spread in both NMRI-nude mice and hairless SCID 
(SHO) mice. Treatment of NMRI-nude mice with anti-Asialo GM1 serum enhanced metastatic 
spread due to substantial depletion of natural killer (NK) cells. However, reproducible 
metastatic spread was only observed in NK cell-defective SCID/beige mice and in hairless 
immunocompetent SKH1 mice bearing disseminated or liver metastases, respectively. Liquid 
chromatography tandem mass spectrometry of urine samples showed that subcutaneous 
and metastasized tumor models exhibit comparable renal monoamine excretion profiles 
characterized by increasing urinary dopamine, 3-methoxytyramine, norepinephrine and 
normetanephrine. Metastases-related epinephrine and metanephrine were only detectable 
in SCID/beige mice. Positron emission tomography and immunohistochemistry revealed 
that all metastases maintained somatostatin receptor-specific radiotracer uptake and 
immunoreactivity, respectively. In conclusion, we demonstrate that intravenous injection of 
luciferase-expressing MPC cells into SCID/beige and SKH1 mice provides reproducible and 
clinically relevant spread of catecholamine-producing and somatostatin receptor-positive 
metastases. These standardized preclinical models allow for precise monitoring of disease 
progression and should facilitate further investigations on theranostic approaches against 
metastatic pheochromocytomas and paragangliomas.
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Introduction
Adrenal pheochromocytomas and extra adrenal 
paragangliomas (PPGLs) are rare catecholamine-
producing tumors of chromaffin cell origin (Lenders et al. 
2005, Harari & Inabnet 2011, Jemal  et  al. 2011). In 
contrast to most other neoplasms, at least 30% of PPGLs 
have a hereditary background with variable development 
of metastatic disease dependent on the mutated gene 
(Lenders  et  al. 2005). Germline mutations in succinate 
dehydrogenase subunit B (SDHB) are associated with 
a particularly high penetrance of metastatic disease 
(Amar et al. 2007). Metastasizing PPGL cells disseminate 
via lymphatics and blood stream and give rise to solid 
organ metastases mainly in lymph nodes, bones, lungs 
and liver (Salmenkivi et al. 2004).
Commonly recommended treatment options for 
metastatic PPGLs include surgery for removing the 
tumor bulk, different combinations of chemotherapy, 
endoradiotherapy using [131I]metaiodobenzylguanidine, 
external radiation therapy to areas such as bone where 
metastases are not accessible for surgery, embolization 
to block tumor blood supply and sometimes also cryo- 
or radiofrequency ablation. However, these treatment 
options are often considered as palliative (PDQ® Adult 
Treatment Editorial Board).
Furthermore, somatostatin type 2 receptor (SSTR2)-
targeting endoradiotherapy offers potential for treating 
metastatic PPGLs, using e.g. [177Lu]Lu-DOTA-(Tyr3)
octreotate ([177Lu]Lu-DOTA-TATE) (Ullrich  et  al. 2016, 
Kong et  al. 2017). Since response rates are usually 
between 30 and 60% (Castinetti  et  al. 2015), this 
approach is likely to benefit from combination with 
adjuvant, for example, radiosensitization therapy. Due to 
the complexity of the metastatic disease, investigations 
on additional, e.g., adjuvant and radiosensitizing 
treatments should be performed using preclinical in 
vivo models reproducibly providing tumors at clinically 
related metastatic sites.
Currently, no fully differentiated human PPGL cell 
line model is available for mirroring human disease in 
mice. An available chromaffin progenitor cell line has been 
established from a primary human pheochromocytoma 
but does not produce catecholamines, limiting its utility as 
a chromaffin cell model (Ghayee et al. 2013). Alternatively, 
the mouse pheochromocytoma (MPC) cell line deriving 
from an adrenal tumor of a neurofibromin 1-knockout 
mouse (Powers et al. 2000) provides an appropriate model 
for preclinical investigations on metastatic PPGLs in vitro 
and in vivo (Korpershoek et al. 2012, Ziegler et al. 2013).
From native MPC cells, a subcutaneous tumor model 
has initially been generated in vivo using NCr-nude mice 
(NU(NCr)-Foxn1nu) reproducibly providing non-metastatic 
allografts (Ohta  et  al. 2006, 2008). Furthermore, also 
NMRI-nude mice (Rj:NMRI-Foxn1nu) have been successfully 
employed for generating a standardized subcutaneous 
tumor model from genetically engineered MPCmCherry cells 
(Ullrich et al. 2014). This particular model resembles at least 
in part biochemical features and molecular characteristics 
of sporadic and hereditary human PPGLs and allows for 
monitoring tumor progression and treatment response 
using both in vivo fluorescence imaging and measurement 
of catecholamines in urine (Ullrich et al. 2016).
The first generation of metastatic pheochromocytoma 
allograft models was based on intravenous tumor 
cell injection into immunodeficient NCr-nude mice 
(NU(NCr)-Foxn1nu) (Ohta  et  al. 2006, Martiniova  et  al. 
2009, Giubellino  et  al. 2012). These models provided 
metastasized allografts occurring predominantly in the 
liver but only rarely in other organs. It is known that 
the immunologic phenotype and the general genetic 
background of mice substantially influence the metastatic 
spread of circulating tumor cells (Khanna & Hunter 2005). 
We therefore hypothesized that intravenous injection 
of MPC cells into mouse strains featuring different 
immunologic phenotypes provides allograft models 
showing a more reproducible pattern of clinically related 
metastases.
To address the above hypothesis, our objective was to 
characterize the metastatic spread of luciferase-expressing 
MPC cells after intravenous injection in mouse strains 
featuring different immunologic phenotypes and to 
compare tumor progression, catecholamine excretion 
and SSTR2 status of different metastases models with a 
previously established subcutaneous reference model 
(NMRI-nude mice) (Ullrich  et  al. 2014, 2016). For 
non-invasive detection of organ metastases in murine 
pheochromocytoma models, MRI and bioluminescence 
imaging (BLI) provide appropriate sensitivity in vivo 
(Martiniova et al. 2011, Giubellino et al. 2012). To quantify 
MPC tumor burden, measurement of urinary monoamines 
provides comparable sensitivity to preclinical imaging 
as has been demonstrated by us in a subcutaneous 
allograft model (Ullrich et al. 2014). In the same model, 
positron emission tomography (PET) using radiolabeled 
somatostatin analogs allowed for functional imaging of 
SSTR2 (Ullrich et al. 2016).
Using the aforementioned tools, two mouse strains 
(SCID/beige and SKH1) were identified providing a 
highly reproducible and clinically relevant pattern of 
https://doi.org/10.1530/ERC-18-0136
http://erc.endocrinology-journals.org © 2018 The authors
Printed in Great Britain
Published by Bioscientifica Ltd.
This work is licensed under a Creative Commons 
Attribution 4.0 International License.
Downloaded from Bioscientifica.com at 11/22/2018 12:38:06PM
via Universitaet Zürich and MULTI-PFIZER
995M Ullrich et al. Mouse models of metastasized 
pheochromocytoma
25:12Endocrine-Related 
Cancer
metastasized allografts that can be precisely monitored. 
These models should facilitate preclinical investigations 
on theranostic approaches against metastatic PPGLs and 
help to further understand biological features of these 
tumors.
Materials and methods
Cell culture and luciferase gene transfer
Mouse pheochromocytoma cells (MPCs clone 4/30PRR 
(Powers et al. 2000)) were routinely cultured as described 
previously (Ullrich  et  al. 2014). MPC cells (passage 32) 
were genetically modified using the lentiviral transfer 
vector p6NST50-luc (Supplementary Fig.  1, see section 
on supplementary data given at the end of this article) 
harboring the open reading frame of a firefly luciferase 
(luc) and a combined expression cassette of enhanced 
green-fluorescent protein and zeocin resistance (egfp-zeo) 
(Morgenroth  et  al. 2007, Stirnnagel  et  al. 2010, 
Ho  et  al. 2012). Genetically modified cells were named 
MPCLUC/eGFP-ZEO (abbreviated as MPCLUC/GZ). Selection of 
genetically modified cells was performed using 100 µg/mL 
zeocin (Thermo Fisher Scientific). Cultures containing 
>90% of genetically modified cells were used for 
experiments (Supplementary Fig. 2A and B).
Animal experiment
Animal experiments were carried out at the Helmholtz-
Zentrum Dresden-Rossendorf according to the guidelines 
of German Regulations for Animal Welfare and have 
been approved by the Local Animal Ethics Committee 
for Animal Experiments (Landesdirektion Dresden, 
Germany). Female mice, between 10 and 14  weeks 
old, were housed in a pathogen-free facility. For tumor 
induction, an injectable suspension containing 2 × 106 
MPCLUC/GZ cells in phosphate-buffered saline was 
prepared. For generation of the subcutaneous reference 
model a single bolus of 40 µL cell suspension was 
injected into the right shoulder of NMRI-nude mice 
(Rj:NMRI-Foxn1nu, T cell-deficient, hairless; Janvier Labs, 
Le Genest-Saint-Isle, France; n = 10). For generation 
of metastases models, a single bolus of 100 µL cell 
suspension was injected intravenously into the tail vein of 
NMRI-nude mice (n = 10), natural killer (NK) cell-depleted 
NMRI-nude mice (n = 5), SHO mice (Crl:SHO-Prkdcscid HrHr, 
T and B cell-deficient, hairless; Charles River Laboratories; 
n = 9), SCID/beige mice (CB17.Cg-PrkdcscidLystbg-J/Crl, 
T and B cell-deficient, NK cell-defective, white-haired; 
Charles River; n = 9) and SKH1 mice (Crl:SKH1-Elite-
Hrhr, immunocompetent, hairless; Charles River; n = 15). 
Anesthesia was induced and maintained with inhalation 
of 10% (v/v) desflurane (Baxter, Unterschleißheim, 
Germany) in 30% (v/v) oxygen air. Animals were killed 
using CO2 inhalation and cervical dislocation. For 
histologic examination, tumors and organs were excised 
and fixed using 4% (w/v) paraformaldehyde in Dulbecco’s 
phosphate-buffered saline containing 2% (w/v) sucrose. 
Bone samples were decalcified for 3 days in decalcifier soft 
(Carl Roth, Karlsruhe, Germany).
NK cell-depleting pre-treatment of NMRI-nude mice
For depletion of NK cells in NMRI-nude mice, animals 
(n = 5) were pre-treated with 30 µL of anti-Asialo GM1 
serum (Wako Chemicals GmbH, Neuss, Germany) diluted 
in Dulbecco’s phosphate-buffered saline and administered 
intraperitoneally 24 h before intravenous tumor cell 
injection. Treatment was repeated 2, 6, 9, 13 and 16 days 
after tumor cell injection.
Bioluminescence imaging
BLI was performed using the In vivo Xtreme system 
(Bruker, Billerica, MA, USA). d-Luciferin was prepared 
and administered according to the manufacturer’s 
instructions (Caliper Life Sciences, Hopkinton, MA, USA). 
Images were analyzed using the MI 7.2 software (Bruker). 
In vitro, net luminescence intensity (photons/s/mm2) of 
serially diluted tumor cells was determined in a 96-well 
microplate (n = 2). In vivo, net luminescence intensities 
were determined from dynamic image series. Signals 
from successfully induced subcutaneous tumors in NMRI-
nude mice (n = 10) were quantified from sagittal view 
images. Signals from successfully induced metastases in 
NMRI-nude (n = 7), NK cell-depleted NMRI-nude (n = 5), 
SHO (n = 6), SCID/beige (n = 9) and SKH1 mice (n = 12) 
were quantified by summating the intensities of ventral 
and dorsal view images. X-ray images were merged with 
bioluminescence images using the linear dodge blending 
mode of Photoshop CS5 (Adobe).
Positron emission tomography
PET was performed as described previously (Ullrich et al. 
2016) using the preclinical nanoSCAN PET/CT 
scanner (Mediso, Münster, Germany). Tumor-bearing 
SCID/beige mice (n = 2) and SKH1 mice (n = 2) received 
15 MBq of [68Ga]Ga-DOTA-(Tyr3)octreotide (TOC) or 
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[68Ga]Ga-DOTA-(Tyr3)octreotate (TATE) at a molar activity 
of 25 GBq/µmol, respectively. Images were merged with 
X-ray CT.
Determination of free urinary monoamines
Single-voided urine samples of NMRI-nude mice bearing 
subcutaneous tumors (n = 10), of SCID/beige mice 
bearing disseminated metastases (n = 9) and of SKH1 
mice bearing liver metastases (n = 7) were collected and 
urinary concentrations of monoamines were determined 
simultaneously using liquid chromatography tandem 
mass spectrometry as described elsewhere (Peitzsch et al. 
2013, Ullrich et al. 2014).
SSTR2 immunohistochemistry
SSTR2 immunohistochemistry was performed on 
paraformaldehyde-fixed paraffin-embedded tissue samples 
from SCID/beige mice bearing disseminated metastases 
(n = 3) and from SKH1 mice bearing liver metastases (n = 3) 
using the anti-SSTR2 (UMB1) primary antibody (Abcam) 
as described previously (Ullrich et al. 2016).
Statistical analysis
Statistical analysis was performed using Prism, version 
5.02 (GraphPad Software). Data are presented as 
mean ± standard error of the mean and n represents the 
number of data sets investigated. Exponential tumor 
progression curves were fitted from luminescence 
intensity data using the least squares method weighted 
by 1/y2. Time of tumor formation (when luminescence 
intensity of tumors exceeded the luminescence 
intensity of initially injected tumor cells) and tumor 
growth rates (% growth per day) were calculated from 
fitted data. Significance of differences was tested using 
ANOVA applying Holm–Šídák’s post hoc multiple 
comparison test. Differences were considered significant 
at P values <0.05. Significance of relationships was 
tested using Pearson’s linear correlation test and 
displayed as Pearson’s correlation coefficient (rp).
Results
BLI of MPCLUC/GZ cells in vitro and initial cell 
distribution in vivo
Luciferase-expressing mouse pheochromocytoma 
(MPCLUC/GZ) cells were generated (Supplementary Figs 1, 
2A and B) to perform non-invasive detection of tumor 
formation in mice. In vitro, BLI detected a minimum of 
125 tumor cells seeded in a 96-well microplate (Fig. 1A). 
Correlation analysis showed a significant positive linear 
relationship (rp = 0.99) between number and luminescence 
intensity of tumor cells indicating that BLI allows for 
precise tumor cell quantification.
As exemplary shown for the NMRI-nude strain, 
in vivo BLI detected a local accumulation of subcutaneously 
injected MPCLUC/GZ cells restricted to the injection site in 
the right shoulder (Fig. 1B, reference model). In the same 
strain, accumulation of intravenously injected MPCLUC/GZ 
cells was detectable in lungs, liver and spleen (Fig.  1B). 
A comparable distribution of intravenously injected 
MPCLUC/GZ cells was also observed in NK cell-depleted 
NMRI-nude, SHO, SCID/beige and SKH1 mice with slightly 
different dynamics (Supplementary Fig. 3A and B).
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Figure 1
BLI of MPCLUC/GZ cells in vitro and in vivo; (A) imaging sensitivity and 
correlation between number and luminescence intensity of serially 
diluted MPCLUC/GZ cells in a 96-well microplate; n = 2; significance of 
relationship: ‡P < 0.001; (B) distribution of MPCLUC/GZ cells in NMRI-nude 
mice 20 min after subcutaneous vs intravenous injection; (iv) intravenous, 
(li) liver, (lu) lung, (sc) subcutaneous, (sp) spleen. A full colour version of 
this figure is available at https://doi.org/10.1530/ERC-18-0136.
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Engraftment of MPCLUC/GZ cells and metastatic 
spread in different mouse strains
Subcutaneous injection of MPCLUC/GZ cells into our 
reference model, NMRI-nude mice, resulted in an 
engraftment rate of 100%. Intravenous tumor cell 
injection resulted in engraftment rates of 70% in 
NMRI-nude mice, 100% in NK cell-depleted NMRI-nude 
mice, 67% in SHO mice, 100% in SCID/beige mice and 
80% in SKH1 mice (Table 1).
In vivo, BLI of MPCLUC/GZ allografts (Fig. 2A) showed 
that subcutaneous cell injection into NMRI-nude mice 
induced ectopic non-metastasizing tumors. Intravenous 
cell injection was associated with a non-consistent 
pattern of sporadically scattered metastases in untreated 
NMRI-nude mice, NK cell-depleted NMRI-nude mice 
and SHO mice. In contrast, intravenous tumor cell 
injection into SCID/beige mice provided a consistent 
pattern of multifocal disseminated metastases in liver, 
adrenal glands, bones, lungs, ovaries, and, rarely, also in 
brain and attached to the peritoneum (Supplementary 
Figs  4A, B, C, D, E, F, G, H, 5A, B, C, D, E, F, G, H, I 
and 6A, B, C, D, E, F). Furthermore, intravenous tumor 
cell injection into SKH1 mice predominantly induced 
multifocal liver metastases (Supplementary Fig.  7A, B 
and C).
Progression of metastasized MPCLUC/GZ allografts in 
different mouse strains
Correlation analyses (Supplementary Fig. 8A, B, C and D) 
showed a significant positive linear relationship between 
tumor volume as determined using MRI (Supplementary 
information for methodologic details and discussion) and 
luminescence intensity of subcutaneous MPCLUC/GZ tumors 
in NMRI-nude mice (rp = 0.77) as well as between tumor 
volume and luminescence intensity of liver metastases in 
SKH1 mice (rp = 0.82). These results indicate that BLI allows 
for semi-quantitative in vivo monitoring of MPCLUC/GZ cell-
derived subcutaneous tumors and metastases in mice with 
comparable accuracy.
Monitoring the luminescence intensities of 
progressing MPCLUC/GZ allografts in vivo (Fig. 2B) showed 
that tumor formation (time when luminescence 
intensity of tumors exceeded the luminescence intensity 
of initially injected tumor cells) occurred 15 days after 
subcutaneous cell injection in NMRI-nude mice. After 
intravenous cell injection, formation of metastases was 
significantly delayed, requiring 38  days in untreated 
NMRI-nude mice, 32 days in NK cell-depleted NMRI-nude 
mice and 39 days in SHO mice. In contrast, formation 
of disseminated metastases already occurred 1.3  days 
after intravenous cell injection in SCID/beige mice even 
Figure 2
BLI of subcutaneous and metastasized MPCLUC/GZ 
allografts in mice featuring different 
immunologic phenotypes; (A) metastatic spread 
at defined time points after cell injection; of 
note, images were individually scaled to 1/10 of 
the maximal luminescence intensity to also 
visualize small lesions, therefore, signal 
dimensions do not represent tumor size;  
(B) progression of luminescence intensities of 
subcutaneous tumors and metastases in vivo; 
logarithmic scaling of y-axis; (white data points, 
dotted lines) luminescence intensity of initially 
distributed tumor cells detected 32 min after 
subcutaneous and 20 min after intravenous cell 
injection (black data points, continuous lines) 
luminescence intensities of progressing tumors; 
depletion of natural killer (NK) cells resulted from 
treatment with anti-Asialo GM1 serum; the 
meaning of scattered metastases and 
disseminated metastases is given in the results 
section; (iv) intravenous, (sc) subcutaneous; 
1animal models showing reproducible pattern of 
metastases. A full colour version of this figure is 
available at https://doi.org/10.1530/ERC-18-0136.
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though these particular bioluminescence signals were 
most likely emitted from surviving tumor cells along the 
tail vein injection route. Liver metastases in SKH1 mice 
were detected 19  days after intravenous cell injection 
and showed a significantly higher exponential growth 
rate (40%/day) compared to the other metastases models 
(between 17 and 27%/day).
Initial BLI measurements showed that after 
intravenous MPCLUC/GZ cell injection, NMRI-nude, NK 
cell-depleted NMRI-nude and SHO mice did not meet the 
requirements for reproducible induction of metastases. 
Therefore, further characterization of metastatic 
phenotypes was only carried out in SCID/beige and 
SKH1 mice and pathophysiology was compared to the 
subcutaneous NMRI-nude reference model.
Renal monoamine excretion related to subcutaneous 
vs metastasized MPCLUC/GZ allografts
Measurement of urinary catecholamines and their 
respective O-methylated metabolites (Fig.  3A) revealed 
that subcutaneous MPCLUC/GZ tumors in NMRI-nude 
mice, disseminated metastases in SCID/beige mice and 
liver metastases in SKH1 mice, were all associated with 
comparable changes in renal monoamine excretion 
profiles characterized by increasing concentrations of 
dopamine, norepinephrine, 3-methoxytyramine and 
normetanephrine. In SCID/beige mice, a significantly 
lower basal monoamine excretion exceptionally allowed 
for additional detection of small changes in metastases-
related urinary epinephrine and metanephrine.
Figure 3
Renal monoamine excretion of subcutaneous and 
metastasized MPCLUC/GZ allograft models;  
(A) pathophysiologic changes in monoamine 
excretion profiles related to subcutaneous tumors 
in NMRI-nude mice, disseminated metastases in 
SCID/beige mice and liver metastases in SKH1 
mice; (white data points, dashed line) physiologic 
excretion profile before tumor cell injection; 
(black data points, continuous line) excretion 
profile after a defined time of tumor growth; 
double-lined circles mark increasing urinary 
concentrations of epinephrine and metanephrine 
detectable in SCID/beige mice; (B and C) 
correlation between luminescence intensity of 
stumors and urinary concentrations of free 
catecholamines and O-methylated catecholamine 
metabolites; logarithmic scaling of x- and y-axes; 
significance of differences or relationships: 
*P < 0.05, ‡P < 0.001; (DA) dopamine, (EPI) 
epinephrine, (MN) metanephrine, (MTY) 
3-methoxytyramine, (NE) norepinephrine, (NMN) 
normetanephrine, (iv) intravenous, (sc) 
subcutaneous.
https://doi.org/10.1530/ERC-18-0136
http://erc.endocrinology-journals.org © 2018 The authors
Printed in Great Britain
Published by Bioscientifica Ltd.
This work is licensed under a Creative Commons 
Attribution 4.0 International License.
Downloaded from Bioscientifica.com at 11/22/2018 12:38:06PM
via Universitaet Zürich and MULTI-PFIZER
1000M Ullrich et al. Mouse models of metastasized 
pheochromocytoma
25:12Endocrine-Related 
Cancer
Correlation analyses (Fig.  3A, B and C) showed 
significant linear relationships between luminescence 
intensities of MPCLUC/GZ tumors and urinary concentrations 
of three urinary monoamines in the subcutaneous 
NMRI-nude reference model (norepinephrine, 
3-methoxytyramine, normetanephrine), compared 
to five urinary monoamines in the disseminated 
SCID/beige metastases model (dopamine, epinephrine, 
3-methoxytyramine, normetanephrine, metanephrine) 
and five urinary monoamines in the SKH1 liver metastases 
model (dopamine, norepinephrine, 3-methoxytyramine, 
metanephrine, epinephrine). Of note, significant linear 
relationships with luminescence intensities of tumors 
were more frequently observed among O-methylated 
catecholamine metabolites compared to free 
catecholamines. These results indicate that measurement 
of urinary monoamines allows for non-invasive and 
precise quantification of metastasized MPCLUC/GZ allografts 
in mice.
Somatostatin type 2 receptors in metastasized 
MPCLUC/GZ allografts
PET showed specific uptake of the somatostatin 
type 2 receptor (SSTR2)-targeting radiotracer 
[68Ga]Ga-DOTA-TOC in MPCLUC/GZ metastases in bone, 
lung, liver and ovaries of SCID/beige mice (Fig.  4A). 
A second radiotracer [68Ga]Ga-DOTA-TATE, which exhibits 
comparable SSTR2 specificity to [68Ga]Ga-DOTA-TOC, was 
specifically taken up by liver metastases in SKH1 mice 
(Fig. 4B).
Immunohistochemistry on metastasized MPCLUC/GZ  
allografts from SCID/beige and SKH1 mice confirmed 
elevated SSTR2 levels in metastases compared to 
surrounding healthy tissue (Fig. 5A, B, C, D, E, F, G, H, 
I and J). These results indicate that SSTR2 is maintained 
in metastasized MPCLUC/GZ allografts, irrespective of 
metastatic site or mouse strain, emphasizing its utility as a 
molecular theranostic target.
Discussion
The present study characterized mouse strain-specific 
metastatic phenotypes of intravenously induced 
luciferase-expressing MPCLUC/GZ allografts, in particular 
with regard to metastatic spread, tumor progression, 
catecholamine excretion and somatostatin type 2 
(SSTR2) receptor status. The investigated mouse strains 
SKH1, NMRI-nude, SHO and SCID/beige were pre-
selected with regard to increasing severity of genetically 
related immune cell defects according to manufacturer’s 
specifications and due to a hairless or white-haired 
phenotype for better optical imaging of organ metastases 
(for details see ‘Materials and methods’ section). In 
particular, intravenous injection of MPCLUC/GZ cells into 
SCID/beige and SKH1 mice resulted in highly reproducible 
and clinically relevant pattern of catecholamine-
producing and SSTR2-positive metastases. These models 
allow for monitoring the progression of metastases 
precisely by two methods, in vivo BLI and measurement 
of tumor-related urinary monoamines.
In a previous study, we investigated the efficiency 
of radiolabeled DOTA-(Tyr3)octreotate for SSTR2-
targeted imaging ([64Cu]Cu-DOTA-TATE) and treatment 
([177Lu]Lu-DOTA-TATE) of metastatic PPGLs in a 
subcutaneous MPC-mCherry allograft model using 
NMRI-nude mice (Ullrich et al. 2016). For this particular 
radiopharmacologic investigation, the subcutaneous 
tumor model had the advantage that the location of one 
single lesion was known and its size and morphology could 
easily be measured allowing for precise determination of 
radiotracer uptake and treatment response.
Nevertheless, subcutaneous MPC allografts do not 
entirely resemble the microenvironment at clinically 
relevant target organs of PPGL metastasis such as lymph 
nodes, bones, lungs and liver (Salmenkivi et al. 2004). In 
terms of modeling metastases in vivo, injection of tumor 
cells into the blood circulation of mice is a common 
approach. The difficulty thereafter is to monitor disease 
progression. For this purpose, the genetically modified 
luciferase-expressing MPCLUC/GZ cell line was generated 
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Figure 4
PET imaging of SSTR2 in two metastasized MPCLUC/GZ allograft models; 
positron emission tomograms merged with X-ray computed tomograms 
as anatomic references; maximum intensity projections 90 min after 
radiotracer injection; (A) [68Ga]Ga-DOTA-TOC uptake of disseminated 
metastases in SCID/beige mice; (B) [68Ga]Ga-DOTA-TATE uptake of liver 
metastases in SKH1 mice; (*) metastatic sites; (ad) adrenal gland; (bl) 
bladder; (bo) bone, scapula; (ki) kidneys; (li) liver; (lu) lung; (ov) ovary; 
(SUV) standardized uptake value. A full colour version of this figure is 
available at https://doi.org/10.1530/ERC-18-0136.
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allowing for in vivo BLI of metastasized allografts after 
intravenous injection into a tail vein.
Using the intravenous cell injection route, it has to 
be considered that formation of metastasized allografts 
arising from circulating MPCLUC/GZ cells does not depend 
on vascular invasion, pre-metastatic selection and 
epithelial–mesenchymal transition usually occurring 
in metastasizing primary tumors (Labelle & Hynes 
2012, Daphu  et  al. 2013). Thus, these early metastatic 
events cannot be investigated in intravenously induced 
MPCLUC/GZ metastases models. Formation of metastases 
in these models primarily depends on later metastatic 
events such as dissemination of MPCLUC/GZ cells via 
lymph system or blood circulation, extravasation and 
interactions of tumor cells with blood components and 
target tissues.
This study demonstrates that metastatic phenotypes 
of intravenously induced MPCLUC/GZ allograft models 
strongly depend on genetic background and immunologic 
condition of the mouse stain. After intravenous injection, 
MPCLUC/GZ cells did not circulate long, with the majority 
accumulating rapidly in lungs and smaller fractions in 
liver and spleen. In contrast to this initial cell distribution, 
in particular lungs later showed a much lower metastatic 
burden compared to liver; spleen remained free from 
metastases. Our results indicate that the engraftment of 
circulating MPCLUC/GZ cells in murine organs essentially 
depends on the tissue-specific microenvironment rather 
than on the number of entrapped cells.
NMRI-nude mice carrying a homozygous Foxn1nu 
mutation are frequently used for generating tumor allograft 
or xenograft models. These mice lack a thymus and are 
therefore T cell deficient allowing for the engraftment 
of tumor cells or tumor tissue without activation of 
adaptive immune responses. Since NMRI-nude mice 
have been successfully employed for generating a 
standardized subcutaneous tumor model from genetically 
engineered MPCmCherry cells (Ullrich et al. 2014, 2016), we 
consequently investigated whether this particular strain 
would also allow for generating a standardized metastases 
model after intravenous injection of MPCLUC/GZ cells. 
Under the investigated conditions, only subcutaneous 
cell injection allowed for reproducible engraftment of 
MPCLUC/GZ cells in NMRI-nude mice, whereas intravenous 
cell injection led to inefficient engraftment and non-
reproducible metastatic scatter. Since combined T and 
B cell deficiency in SHO mice carrying a homozygous 
Prkdcscid mutation did not improve the engraftment of 
circulating MPCLUC/GZ cells, we suspect innate immune 
responses to be responsible.
Figure 5
SSTR2 immunohistochemistry of metastasized MPCLUC/GZ allografts in  
SCID/beige and SKH1 mice: (A, I) liver metastases showing initial necrosis;  
(B, J) IgG isotype control stain of liver metastases; (C, D) small scattered 
metastases from periphery of lung tissue; (E) adrenal metastasis surrounded 
by adrenocortical tissue; (F) ovarian metastasis connected to uterine tissue; 
(G, H) nests of bone metastases surrounded by bone marrow; (*) 
metastasized allografts; (bm) bone marrow; (cb) cortical bone; (co) 
adrenocortical tissue; (iv) intravenous, (ki) kidney; (li) liver tissue; (lu) lung 
tissue; (mu) muscle tissue; (sc) subcutaneous; (ut) uterine tissue; scale bar: 
0.5 mm. A full colour version of this figure is available at https://doi.
org/10.1530/ERC-18-0136.
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NK cells are essential effectors in the response to tumor 
formation. Consistent with previous reports showing that 
the genetic background of NMRI-nude and SHO mice is 
associated with high NK cell numbers (Dorshkind  et  al. 
1985, Budzynski & Radzikowski 1994), both strains not 
only showed suboptimal engraftment of circulating 
MPCLUC/GZ cells, but also the longest delay in tumor 
formation. In support of our hypothesis, in vivo depletion 
of NK cells selectively performed in NMRI-nude mice 
using anti-Asialo GM1 serum facilitated the engraftment 
of circulating MPCLUC/GZ cells and preponed tumor 
formation; however, number and activity of NK cells were 
not determined in these mice. Additional interactions 
of anti-Asialo GM1 serum with murine monocytes, fetal 
thymocytes and basophils might have also contributed 
(Habu et al. 1981, Kasai et al. 1981, Nishikado et al. 2011).
In SCID/beige mice, impaired NK cell function 
due to the Lystbg-J mutation in addition to T and B cell 
deficiency (MacDougall  et  al. 1990) was associated with 
highly efficient engraftment of circulating MPCLUC/GZ cells 
and almost immediate tumor formation. These findings 
indicate that NK cells are substantially involved in the 
innate immune response against circulating MPCLUC/GZ 
cells. Thus, it appears that well-directed NK cell response 
against circulating tumor cells may allow for protective 
treatment against metastasizing PPGL cells.
The highly reproducible pattern of disseminated 
MPCLUC/GZ metastases in SCID/beige mice provides an 
opportunity for studying metastasis to the bone, one of 
the most frequent target organs of metastatic PPGLs in 
patients. Furthermore, MPCLUC/GZ metastases occurring in 
the adrenal glands of SCID/beige mice morphologically 
resemble orthotopic tumors, potentially enabling studies 
on primary pheochromocytomas, too.
SKH1 mice are capable of generating both innate and 
adaptive immune responses against circulating MPCLUC/GZ 
cells. Interestingly, only liver tissue of SKH1 mice provided 
an adequate hosting microenvironment for successful 
engraftment of MPCLUC/GZ cells presumably due to organ-
specific immunologic tolerance or further unknown 
processes. Most importantly, MPCLUC/GZ liver metastases 
in SKH1 mice prospectively allow for therapeutic 
investigations in the presence of an entirely functional 
immune system.
For BLI of metastasized pheochromocytoma allografts 
in mice, other genetically modified luciferase-expressing 
cell lines such as MPC-GL9 (Powers  et  al. 2014) and 
mouse tumor tissue (MTT)-luc (Giubellino  et  al. 2012) 
have been generated previously. However, MPC-GL9 
cells lack an antibiotic resistance for selection in vitro and 
MTT-luc cell-derived tumors have shown uncommonly 
high aggressiveness in vivo. In contrast, zeocin resistance 
of the MPCLUC/GZ cell line allowed for efficient selection of 
genetically modified clones in vitro. Moreover, MPCLUC/GZ 
cell-derived metastases in mice progressed with reasonable 
aggressiveness and therefore provide an appropriate time 
frame for therapeutic testing.
The present study demonstrates that measurement 
of renal monoamine excretion in SCID/beige and SKH1 
mice, in particular of dopamine, 3-methoxytyramine and 
normetanephrine, allows for most precise non-invasive 
quantification of metastasized MPCLUC/GZ allografts. 
Thus, this preclinical diagnostic approach follows clinical 
procedures based on measurements of metanephrines 
in plasma and urine for detecting PPGLs (Lenders & 
Eisenhofer 2017).
Although MPC cells are known to express 
phenylethanolamine N-methyltransferase (PNMT), the 
key enzyme of epinephrine synthesis (Powers et al. 2000), 
considerable increases particularly in urinary epinephrine 
and its O-methylated metabolite metanephrine were 
only detectable in SCID/beige mice bearing disseminated 
MPCLUC/GZ metastases. The prevalent appearance of 
adrenal metastases in SCID/beige mice may explain 
these observations since adrenal cortical steroids are 
known to induce PNMT in primary pheochromocytomas 
(Eisenhofer  et  al. 2011). Furthermore, a low basal 
monoamine excretion and a high metastatic burden in 
SCID/beige mice may also have facilitated the detection 
of tumor-related epinephrine and metanephrine in 
urine. Taken together, measurement of tumor-related 
monoamines in urine provides a reliable alternative to 
small animal imaging approaches in terms of monitoring 
the overall burden of metastasized MPCLUC/GZ allografts 
in mice.
PET and immunohistochemistry showed that SSTR2 
is a molecular theranostic target also in metastasized 
MPCLUC/GZ allografts, irrespective of metastatic site or 
mouse strain. These findings are in agreement with clinical 
findings of high SSTR2 densities in metastatic human 
PPGLs, especially in those due to mutations in succinate 
dehydrogenase subunit 2 (SDHB) (Elston  et  al. 2015, 
Janssen  et  al. 2015, Tan  et  al. 2015). Thus, metastasized 
MPCLUC/GZ allografts may be a predictor of metastatic 
lesion responses to SSTR2-targeting treatments.
In conclusion, this study demonstrates that intravenous 
injection of MPCLUC/GZ cells into SCID/beige and SKH1 
mice provides reproducible and clinically relevant 
pattern of catecholamine-producing and SSTR2-positive 
metastases. These preclinical models allow for monitoring 
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disease progression precisely using BLI and measurements 
of tumor-related urinary monoamines. Prospectively, 
MPCLUC/GZ metastases models will facilitate investigations 
on therapeutic approaches against metastatic PPGLs based 
on combinations of SSTR2-targeted endoradiotherapy 
with adjuvant and radiosensitizing drugs, for example, 
cyclooxygenase 2-selective inhibitors (Laube et al. 2016).
Supplementary data
This is linked to the online version of the paper at https://doi.org/10.1530/
ERC-18-0136.
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